Complement Inhibition for the Treatment of Myasthenia Gravis

Generalized myasthenia gravis (gMG) is a rare autoimmune disorder affecting the neuromuscular junction (NMJ). Approximately 80–90% of patients display antibodies directed against the nicotinic acetylcholine receptor (AChR). A major drive of AChR antibody-positive MG pathology is represented by compl...

Descripción completa

Detalles Bibliográficos
Autores principales: Mantegazza, Renato, Vanoli, Fiammetta, Frangiamore, Rita, Cavalcante, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751298/
https://www.ncbi.nlm.nih.gov/pubmed/33365280
http://dx.doi.org/10.2147/ITT.S261414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751298/
https://www.ncbi.nlm.nih.gov/pubmed/33365280
http://dx.doi.org/10.2147/ITT.S261414

Ejemplares similares